Bli medlem
Bli medlem

Du är här


FIT Biotech Oy: FIT Biotech to repeat it's proof-of-concept gene-based treatment study


Company announcement
September 5, 2016 at 15:30 EET

FIT Biotech to repeat it's proof-of-concept gene-based treatment study

FIT Biotech plans to repeat it's pivotal proof-of-concept study in gene-based
treatment due to an unexpected malfunction of the electroporation device
(EP). The EP device is used to enhance uptake of DNA-plasmid into targeted
cells. The study will be repeated with a new EP device and it is expected to
be completed and reported in Q1/2017.
FIT Biotech's other projects as listed in the May 20, 2016, and the June 10,
2016, company releases are progressing according to the operational plan.

Further information:
James Kuo
CEO, FIT Biotech Oy
Tel: +358 3 3138 7000

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops
and licenses its patented GTU® (Gene Transport Unit) vector technology for
new-generation medical treatments. GTU® is a gene transport technology that
meets an important medical challenge in the usability of gene therapy and DNA

FIT Biotech applies GTU® technology in its drug development programs.
Application areas include cancer (gene therapy) and infectious diseases such
as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland market maintained by
Nasdaq Helsinki Oy.

Nasdaq Helsinki
Principal media


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.